Imovax d.T. Adult Dosage/Direction for Use

Posology: The following schedule is recommended as primary vaccination series: 1st dose in the chosen date; 2nd dose 1-2 months after the 1st dose; 3rd dose 6-12 months after the 2nd dose.
After the primary vaccination series is completed, a single dose of 0.5 mL as booster dose every five to ten years is recommended.
In case of vaccination because of wounds, it will be worth considering the need for active immunisation, with or without passive immunisation (anti-tetanus immunoglobulin) depending on the type of wound, and the patient's vaccination history. Anti-tetanus immunoglobulin should be administered in an injection site different from that used for vaccination.
Minor or clean wounds: When it is known that the person has completed his/her primary vaccination series against tetanus and has received his/her last booster dose in the last ten years, revaccination or the use of anti-tetanus immunoglobulin is not recommended. In people who have not completed their primary vaccination series, when this is unknown, or when the immunisation status is uncertain, or more than ten years have passed since the last booster dose, vaccination is recommended. In all these cases anti-tetanus immunoglobulin is not required.
Other types of wounds, such as major and contaminated: Vaccination will always be carried out, unless the person has completed his/her primary vaccination series against tetanus and has also received his/her last booster dose in the last five years. In people who have not completed their primary vaccination series against tetanus, when this is unknown, or when the immunisation status is uncertain, anti-tetanus immunoglobin should be administered in addition to the vaccine.
Method of administration: Before vaccination, the vaccine needs to be thoroughly shaken and visually observed to confirm that its appearance is as usual and that it does not contain any foreign particles.
The 0.5 mL content should be injected intramuscularly. The recommended injection site is the deltoid area (except in small children).
People who suffer from bleeding diathesis should be vaccinated by deep subcutaneous injection.
The vaccine should not be administered intradermally. It should never be administered intravenously.